I personally believe Rabin is doing a great job, especially after listening to his 3rd quarter conference call. Rabin has admitted that the prior CEO of the company was garbage, and that the market cap would needed to be proven through science as every deal done in the past has been a "colossal nightmare which hemorrhaged value." There is clear proof to this, as Rabin came into ACTC with 51 open litigation matters from the prior CEO, to which they have settled 50 of those claims, and only have one holdout. Rabin said he would like to obviously resolve this issue, although he is not going to make any rash deals just to clear it and be up-listed by year-end (keep in mind the last holdout is most likely very aware that ACTC would like to have it settled by year end, and is using that for leverage).
Rabin truly realizes the potential of this company, and is very good at seeing the long-term picture. The truth is this stock is really not desirable for day-traders or short term traders, as Rabin is relying on the technology to prove itself. In order to realistically get through phase II and phase III of their AMD/SMD trials, I am expecting it to take 2-4 years to fully complete. For long term investors, on the other hand (who are willing to wait years), the current low share price allows a great opportunity to continue adding shares, in hopes that ACTC lives up to its monstrous potential in the future.
Aside from AMD/SMD research, they have other very exciting programs in the working (such as IPS and MSC cells), and Rabin admitted unlike AMD/SMD cells, their facilities would not be able to solely handle the research. For this reason, entering a partnership with a big pharma company is a high priority for 2013. Once again Rabin emphasized that ACTC must move in a "logical, thoughtful progression," and will wait for the right partner, as opposed to partnering just to partner or boost the current, short-term share price.
Perhaps the most important thing that was said, was that the NIH (national institute of health), is reviewing the revision to stem cell guidelines this month (Nov), and ACTC plans on presenting a proposal by Dec. This could end up determining ACTC's cells as "ethical" stem cells, giving them even more leverage along with their 50+ issued patents.
AI
Market Data 
Markets 
